Rheumatoid Arthritis News and Research RSS Feed - Rheumatoid Arthritis News and Research

Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.

RA is an autoimmune disease, meaning the immune system, which is usually geared up to fight infection, attacks the lining of the joints, causing them to swell and become stiff and painful. Eventually, the joint itself can become damaged as well as the cartilage and surrounding bone. Any joint can be affected but most commonly the illness involves the hands, feet and wrists.

The condition is more common among women than men and usually affects people between the ages of 40 and 70, although it can affect people of any age.

Symptoms range from mild to severe and can flare-up suddenly and unpredictably, making the condition very difficult to live with.

The exact cause of rheumatoid arthritis is not yet fully understood but some research suggests that viruses and bacteria may be involved. RA cannot be cured but early diagnosis and treatment can help to manage symptoms and prevent disability.
Researchers use mathematical models to predict how immune cells respond to disease

Researchers use mathematical models to predict how immune cells respond to disease

Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease. [More]
Researchers say that nervous system may play vital role in infections, autoimmune diseases

Researchers say that nervous system may play vital role in infections, autoimmune diseases

The nervous system may play a bigger role in infections and autoimmune diseases than previously known. If researchers can learn more about that role, it could provide insight into diagnosing and treating everything from the stomach flu to rheumatoid arthritis. [More]
Early support and education program has positive impact on people with rheumatoid arthritis

Early support and education program has positive impact on people with rheumatoid arthritis

A study at Hospital for Special Surgery finds that a support group addressing the psychological and educational needs of people recently diagnosed with rheumatoid arthritis (RA) has a strong positive impact on their lives. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

A study by Hospital for Special Surgery researchers finds that body mass index (BMI) plays a role in rheumatoid arthritis (RA) patients' ability to achieve a sustained remission. Looking at patients who had received an RA diagnosis within the past 12 months, investigators found that those who were significantly underweight or overweight/obese were the least likely to remain in remission. [More]
Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that new data on Vectra DA will be featured at the 2014 American College of Rheumatology Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. [More]
Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care LLC, a leading provider of comprehensive specialty pharmacy solutions to the pain management industry and a portfolio company of BelHealth Investment Partners, announced a new national contract under its Comprehensive Hub Solutions Program (the "Program"). [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. [More]
First steps in the origin of pancreatic cancer identified by Mayo Clinic researchers

First steps in the origin of pancreatic cancer identified by Mayo Clinic researchers

Researchers at Mayo Clinic's campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore. [More]
Study points to major role of obesity in triggering, prolonging autoimmune diseases

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases. [More]
New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost. Doctoral researcher Diederik De Cock (KU Leuven) describes the strategy in a new study published in Annals of Rheumatic Diseases. [More]
SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US). [More]
Health benefits of modified formulation of curcumin supplements

Health benefits of modified formulation of curcumin supplements

The health benefits of over-the-counter curcumin supplements might not get past your gut, but new research shows that a modified formulation of the spice releases its anti-inflammatory goodness throughout the body. [More]
New handheld probe can produce detailed images of blood vessels, other internal body parts

New handheld probe can produce detailed images of blood vessels, other internal body parts

A new handheld probe developed by a team of university and industry researchers in the Netherlands and France could give doctors powerful new imaging capabilities right in the palms of their hands. The imaging system, which is described in a paper published in The Optical Society's open-access journal Optics Express, shrinks a technology that once filled a whole lab bench down to a computer screen and a small probe about the size of a stapler. [More]
Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation. [More]
Study reports IL-37's activity in the adaptive immune system

Study reports IL-37's activity in the adaptive immune system

A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens. [More]
BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin. [More]
New study pinpoints complex genetic origins for autoimmune diseases

New study pinpoints complex genetic origins for autoimmune diseases

Scores of autoimmune diseases afflicting one in 12 Americans — ranging from type 1 diabetes, to multiple sclerosis (MS), to rheumatoid arthritis, to asthma — mysteriously cause the immune system to harm tissues within our own bodies. Now, a new study pinpoints the complex genetic origins for many of these diseases, a discovery that may lead to better diagnosis and ultimately to improved treatments. [More]
Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan Holdings Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, and Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, today announce that they have entered into a research collaboration in the area of osteoarthritis pain. [More]
Study identifies new signaling pathway that leads to inflammatory bone erosion in RA patients

Study identifies new signaling pathway that leads to inflammatory bone erosion in RA patients

A new study by researchers at Hospital for Special Surgery identifies a new signaling pathway that contributes to the development and progression of inflammatory bone erosion, which occurs in patients with rheumatoid arthritis (RA). Rheumatoid arthritis is a systemic inflammatory autoimmune disease that affects millions of adults worldwide. [More]